Cipher Pharmaceuticals Inc. (CPH.TO)
| Previous Close | 18.09 |
| Open | 18.23 |
| Bid | 18.09 x 0 |
| Ask | 18.16 x 0 |
| Day's Range | 17.81 - 18.54 |
| 52 Week Range | 4.10 - 19.69 |
| Volume | |
| Avg. Volume | 48,753 |
| Market Cap | 466.224M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | 14.93 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Cipher Pharmaceuticals Reports Second Quarter 2024 Results
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three and six months ended June 30, 2024.
- CNW Group
Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2024 after the market close on Thursday, August 8, 2024. The Company will also hold a conference call on Friday, August 9, 2024 at 8:30AM ET to discuss the results and corporate developments.
- CNW Group
Cipher Pharmaceuticals Acquires Profitable Growth Dermatology Products from ParaPRO for US$89.5 Million
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announces the signing of a definitive asset purchase agreement with ParaPRO LLC ("ParaPRO") and the closing of the acquisition of the global product rights for Natroba™ (Spinosad), as well as the commercial sales team in the United States for total consideration of US$89.5 million.
